Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Optimizing the Timing of Maternal Influenza Vaccination

Infants face a gap in protection against influenza between birth and the time of vaccination. Thus, maternal immunization is the only way to prevent flu infection in pregnant women and newborns. Our current understanding of the optimal timing of vaccination is rudimentary. Watch this webinar with Dr. Michael Dodds to learn how modeling and simulation (M&S) offers an alternate approach to dedicated clinical studies to determine the best time to vaccine pregnant women against influenza.

Speaker(s): Michael Dodds
Solution: PK/PD Modeling & Simulation
Therapeutic Area: Infectious Disease, Pediatrics
More Info

Using Virtual Twin Technology to Predict Drug Exposure in Individual Patients

In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.

Speaker(s): Tom Polasek
Solution: PBPK Modeling & Simulation
Therapeutic Area: Central Nervous System
More Info

Apocalyptic Clinical Pharmacology: A Comprehensive Approach to Drug Development

Watch this webinar with Dr. Graham Scott, Senior Director of Clinical Pharmacology at Certara Strategic Consulting, to learn why you should invest in “apocalyptic clinical pharmacology.” Dr. Scott presented case studies that illustrate how sponsors can benefit from a clinical pharmacology strategy that uses model-informed approaches to inform and “fill in the gaps” of clinical trials.

Speaker(s): Graham Scott
Solution: Clinical Pharmacology Strategy
More Info

Using PML to Perform Mechanistic Pharmacokinetic Modeling

Watch this webinar with Cen Guo—a graduate student at UNC-Chapel Hill—to learn how she used an integrated approach to predict alterations in bile acid disposition due to inhibition of multiple transporters using the model bile acid taurocholate (TCA).

Speaker(s): Cen Guo
Solution: PK/PD Modeling & Simulation
More Info

Using Model-based Meta-analysis to Inform Drug Development for Autoimmune Diseases

MBMA helps sponsors design less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio. Watch this webinar with Dr. Mark Lovern, Vice President at Certara Strategic Consulting, to learn how leveraging public data can provide value by abbreviating the “cash spiral” inherent to proprietary data.

Speaker(s): Mark Lovern
Solution: Model-based Meta-analysis, PK/PD Modeling & Simulation
More Info

How to Perform Level C IVIVC in Phoenix

In this webinar, Professor Jean-Michel Cardot explained how to perform Level C IVIVC using Phoenix. Learn how to calculate pharmacokinetic parameters via the non-compartmental analysis module; how to calculate dissolution parameters via the dissolution module; how to link the in vivo pharmacokinetic parameters and in vitro dissolution parameters via the linear relationship module; and how to calculate dissolution limits.

Speaker(s): Jean-Michel Cardot
Solution: PK/PD Modeling & Simulation
More Info
Learn More LinkedIn Twitter Facebook Email